Core Insights - eXoZymes is set to present a solution for scaling production of NCT, a naturally occurring small molecule with potential applications in nutraceuticals and pharmaceuticals, at the MISTA Symposium on March 18, 2026 [1] - The focus of the presentation will be on NCT's role in metabolic health and its relevance in the evolving landscape of food, supplements, and wellness solutions [1] - The company aims to leverage its proprietary exozyme platform to enable efficient production of NCT, addressing the historical limitations of its rarity in nature [1] Company Overview - eXoZymes Inc. was founded in 2019 and has developed a biomanufacturing platform that utilizes AI-enhanced enzymes, termed "exozymes," to produce valuable natural products sustainably [1] - Exozymes operate outside living cells, allowing for scalable production and replacing traditional toxic petrochemical processes [1] - The company does not intend to trademark the term "exozymes," viewing it as a new nomenclature for the next generation of biomanufacturing [1] Industry Context - The MISTA Symposium will gather leaders from the food, nutrition, and health industries to discuss scientific advances that support healthier aging and improved metabolic resilience [1] - NCT has gained attention for its potential metabolic benefits, which could open new opportunities in the nutraceutical, pharmaceutical, and specialty ingredient markets [1] - The advancements in cell-free enzyme engineering are expected to facilitate the scalable production of previously impractical molecules [1]